Dichiarazione congiunta U.S. Department of Agriculture e the U.S. Food and Drug Administration
Il mese scorso, il Dipartimento dell'Agricoltura degli Stati Uniti e la Food and Drug Administration degli Stati Uniti hanno tenuto un incontro pubblico per discutere l'uso di linee cellulari di bestiame e pollame, per sviluppare prodotti alimentari derivate da colture cellulari.
Over the past five years, more Americans of all ages are rolling out their yoga mats and meditating. A large nationally representative survey shows that the number of American adults and children using yoga and meditation has significantly increased over previous years and that use of chiropractic care has increased modestly for adults and held steady for children.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it will present data on investigational compounds in the AML Franchise pipeline of the Daiichi Sankyo Cancer Enterprise at the 60th Annual Meeting of the American Society of Hematology (ASH) from December 1-4 in San Diego.
Three patients with chronic paraplegia were able to walk over ground thanks to precise electrical stimulation of their spinal cords via a wireless implant. In a double study published in Nature and Nature Neuroscience, Swiss scientists Grégoire Courtine (EPFL and CHUV/Unil) and Jocelyne Bloch (CHUV/Unil) show that, after a few months of training, the patients were able to control previously paralyzed leg muscles even in the absence of electrical stimulation.
Bain Capital, LP and Pfizer Inc. today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three clinical- stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.
Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show. (1)
Including exercise or sport as part of cancer care can significantly improve symptom management, quality of life and fitness during and after treatment, French researchers have concluded in two presentations to be reported at the ESMO 2018 Congress in Munich. Even among patients at highest risk of poor quality of life, exercise can make a difference.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will be presenting results from 13 abstracts across the company’s rheumatology portfolio and pipeline products during the 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting taking place in Chicago, IL, from 19–24 October.